论文部分内容阅读
目的:了解本院鲍曼不动杆菌(Acinetobacter baumannii,AB)的临床分布特点以及耐药性变迁,为临床有效预防和治疗AB感染提供依据。方法:回顾性分析本院2014年1月~2015年12月检出的1173 AB的标本来源、科室分布以及耐药性变迁。结果:2014年和2015年均以AB检出最多,分别占14.70%、16.94%。AB标本来源主要是痰(1013株,86.36%)。科室分布主要来自重症监护病房(intensive care unit,ICU)(综合ICU和心胸脑外科ICU)(686株,58.48%),其次是呼吸内科(105株,8.95%)、心血管内科(66株,5.63%)。ICU的多重耐药鲍曼不动杆菌(Multidrug-resistant Acinetobacter baumannii,MDR-AB)的检出率显著高于非ICU,差异有统计学意义(P<0.01)。14种常用抗菌药物的药敏结果显示:ICU除头孢噻肟外,AB耐药率总体呈上升趋势,差异均有统计学意义(P<0.01);非ICU除头孢吡肟外,AB耐药率总体呈上升趋势,差异均有统计学意义(P<0.05)。结论:AB的临床分布以ICU病房最多,且耐药性最强。
OBJECTIVE: To understand the clinical distribution and drug resistance of Acinetobacter baumannii (AB) in our hospital and provide a basis for clinical prevention and treatment of AB infection. Methods: A retrospective analysis of 1173 AB samples from January 2014 to December 2015 in our hospital was conducted. The distribution of departments and changes in drug resistance were analyzed. Results: AB was detected the most in 2014 and 2015, accounting for 14.70% and 16.94% respectively. The main source of AB specimens was sputum (1013 strains, 86.36%). The department distribution mainly came from intensive care unit (ICU) (ICU and ICU) (686, 58.48%), followed by respiratory medicine (105, 8.95%), cardiology (66, 5.63%). The detection rate of multidrug-resistant Acinetobacter baumannii (MDR-AB) in ICU was significantly higher than that in non-ICU (P <0.01). The drug susceptibility results of 14 commonly used antibacterials showed that in addition to cefotaxime, ICU resistance rates of ABU generally showed an upward trend (P <0.01). In addition to cefepime, AB drug resistance The rates were generally rising, the differences were statistically significant (P <0.05). Conclusion: The clinical distribution of AB is the most in ward of ICU and the strongest resistance.